Jump to: | Authorized Access | | | Attribution | | | Authorized Requests |
- Study Description
-
Important Links and Information
-
Request access via Authorized Access
- Instructions for requestors
- Data Use Certification (DUC) Agreement
- Talking Glossary of Genetic Terms
The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131). The goal of this study is to identify the molecular basis for response and resistance to targeted therapies that are matched to specific genomic alterations found in their cancers. Arm R is one of the treatment sub-protocols within the NCI-MATCH Clinical Trial (EAY131) where patients with BRAF fusions, non-V600K or non-V600E mutations, are treated with Trametinib. This subprotocol is one of the treatment arms included in the CS-MATCH-0007 protocol and will provide specimens for the program including DNA from tumor tissue and whole blood.
- Study Weblinks:
- Study Design:
- Clinical Trial
- Study Type:
- Cohort
- Exome Sequencing
- RNA Sequencing
- Total number of consented subjects: 28
- Subject Sample Telemetry Report (SSTR)
-
Request access via Authorized Access
- Authorized Access
- Publicly Available Data
- Link to other NCBI resources related to this study
-
- BioProject
- Gene
- PMC
- Clinical Trials
- Study Inclusion/Exclusion Criteria
Patients must fulfill all applicable eligibility criteria outlined in the MATCH Master Protocol.
- Selected Publications
- Diseases/Traits Related to Study (MeSH terms)
-
- Primary Phenotype: Neoplasms
- Links to Related Genes
- Authorized Data Access Requests
-
See research articles citing use of the data from this study
- Study Attribution
-
-
Principal Investigator
- Lyndsay Harris, MD. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
-
Funding Source
- Division of Cancer Treatment and Diagnosis. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
-
Principal Investigator